Blinatumomab for MRD1 B-all: The evidence strengthens

Research output: Contribution to journalReview article

Abstract

In this issue of Blood, Gökbuget et al provide strong evidence that immunotherapy with blinatumomab can eliminate residual chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL) cells and that this prevents subsequent relapse and improves survival.1 This addresses the most important unsolved clinical problem in adults with B-ALL: the development of chemotherapy-resistant relapsed disease.

Original languageEnglish (US)
Pages (from-to)1497-1498
Number of pages2
JournalBlood
Volume131
Issue number14
DOIs
StatePublished - Apr 5 2018

Fingerprint

Chemotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Drug Therapy
Immunotherapy
Blood
Cells
Recurrence
blinatumomab

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Blinatumomab for MRD1 B-all : The evidence strengthens. / Brown, Patrick A.

In: Blood, Vol. 131, No. 14, 05.04.2018, p. 1497-1498.

Research output: Contribution to journalReview article

Brown, Patrick A. / Blinatumomab for MRD1 B-all : The evidence strengthens. In: Blood. 2018 ; Vol. 131, No. 14. pp. 1497-1498.
@article{87c85c76d37e451cb06cb84109bd2ffa,
title = "Blinatumomab for MRD1 B-all: The evidence strengthens",
abstract = "In this issue of Blood, G{\"o}kbuget et al provide strong evidence that immunotherapy with blinatumomab can eliminate residual chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL) cells and that this prevents subsequent relapse and improves survival.1 This addresses the most important unsolved clinical problem in adults with B-ALL: the development of chemotherapy-resistant relapsed disease.",
author = "Brown, {Patrick A}",
year = "2018",
month = "4",
day = "5",
doi = "10.1182/blood-2018-02-830364",
language = "English (US)",
volume = "131",
pages = "1497--1498",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - Blinatumomab for MRD1 B-all

T2 - The evidence strengthens

AU - Brown, Patrick A

PY - 2018/4/5

Y1 - 2018/4/5

N2 - In this issue of Blood, Gökbuget et al provide strong evidence that immunotherapy with blinatumomab can eliminate residual chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL) cells and that this prevents subsequent relapse and improves survival.1 This addresses the most important unsolved clinical problem in adults with B-ALL: the development of chemotherapy-resistant relapsed disease.

AB - In this issue of Blood, Gökbuget et al provide strong evidence that immunotherapy with blinatumomab can eliminate residual chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL) cells and that this prevents subsequent relapse and improves survival.1 This addresses the most important unsolved clinical problem in adults with B-ALL: the development of chemotherapy-resistant relapsed disease.

UR - http://www.scopus.com/inward/record.url?scp=85047614818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047614818&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-02-830364

DO - 10.1182/blood-2018-02-830364

M3 - Review article

C2 - 29622532

AN - SCOPUS:85047614818

VL - 131

SP - 1497

EP - 1498

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -